Answers are grounded in this paper and cite their sources.
Exploratory role of serum FGF-8 as a marker of bone metastasis in tumor progressionH uman FGF is a class of cytokines that significantly impacts tissue disease, metabolism, cell growth, and development.The FGF family comprises 22 members and can be further broken down into paracrine and endocrine subgroups [1].The FGF family is divided into seven subfamilies, including the FGF-1, FGF-4, FGF-7, FGF-8, FGF-9, FGF-11, and FGF-19 subfamilies.Each subfamily is distinguished by the similarity and specificity of its protein structure [2].FGF signaling controls the actions of articular chondrocytes, peripheral synoviocytes, and osteoblasts, essential for maintaining joint health and functional balance [3].The FGF-8 subfamily consists of three proteins: FGF-8, .FGF-17 is essential for brain development, while FGF-18 and FGF-8 are crucial for chondrogenesis and osteogenesis [5].Members of the FGF-8 subfamily exhibit distinct tissue distribution patterns and binding affinities for FGF receptors.FGF-8, also known as androgen-induced growth factor (AIGF) [6], plays a role in stimulating physiological cellular processes such as cell proliferation, differentiation, and migration [7].FGF signaling pathways may be significant in cancer pathophysiology since they have been linked to tumor growth and progression.Cell lines from breast and prostate cancers express .Bone develop-Objectives: FGF-8, a member of the FGF family, plays a crucial role in cellular processes and has been implicated in cancer progression.The study aims to comprehend FGF-8's involvement in bone metastasis, emphasizing its potential as a diagnostic marker and focusing on its association with Bone-Alkaline Phosphatase (B-ALP) and other biochemical parameters.Methods: The case-control study spans 12 months, involving 60 participants, including 30 with secondary bone metastases and an equal number without metastasis.FGF-8 levels were quantified using ELISA, and B-ALP, serum ALP, and various biochemical parameters were assessed.The study employed standardized procedures to minimize bias, including matching cases and controls, and obtaining ethical approval.Results: In patients with bone metastasis, serum ALP levels, particularly B-ALP, were significantly higher.The metastatic group exhibited elevated FGF-8 concentrations, showcasing a positive correlation with B-ALP and serum calcium levels.The study successfully differentiated ALP isoenzymes through heat inactivation and L-phenylalanine inhibition.Additionally, serum calcium levels were markedly elevated in the metastatic group.Conclusion: The findings suggest that FGF-8 is a potential diagnostic marker for bone metastasis, particularly in breast and prostate cancers.Elevated FGF-8 levels correlate with increased B-ALP and serum calcium, indicating its role in osteoblastic differentiation in metastasis.The study proposes the utility of ELISA-based kits for FGF-8 in serum as a practical and efficient method for assessing bone tumor progression.
No takes yet. Share an insight, caveat, or question.
G. Gill (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: